Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
作者信息
Courand Pierre-Yves, Berger Mathilde, Moulayat Chahinaz, Bouali Anissa, Dalle Stéphane
出版信息
JACC CardioOncol. 2023 Dec 19;5(6):848-849. doi: 10.1016/j.jaccao.2023.09.006. eCollection 2023 Dec.
Abstract
摘要
相似文献
1
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC CardioOncol. 2023 Dec 19;5(6):848-849. doi: 10.1016/j.jaccao.2023.09.006. eCollection 2023 Dec.
2
Reply: Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC CardioOncol. 2023 Dec 19;5(6):850. doi: 10.1016/j.jaccao.2023.10.003. eCollection 2023 Dec.
3
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol. 2023 Jun 6;5(5):628-637. doi: 10.1016/j.jaccao.2023.04.004. eCollection 2023 Oct.
4
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
ESC Heart Fail. 2022 Jun;9(3):1914-1919. doi: 10.1002/ehf2.13897. Epub 2022 Mar 31.
5
Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
J Clin Med. 2023 Feb 6;12(4):1278. doi: 10.3390/jcm12041278.
6
Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
Acta Oncol. 2022 Jan;61(1):45-51. doi: 10.1080/0284186X.2021.1992010. Epub 2021 Oct 19.
7
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Cancer Treat Rev. 2021 Nov;100:102282. doi: 10.1016/j.ctrv.2021.102282. Epub 2021 Aug 18.
8
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
Breast Cancer Res Treat. 2021 Jul;188(1):149-163. doi: 10.1007/s10549-021-06192-w. Epub 2021 Apr 5.
9
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
Int J Cardiol. 2022 Feb 15;349:134-137. doi: 10.1016/j.ijcard.2021.11.059. Epub 2021 Nov 27.
10
Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
J Clin Med. 2022 Feb 5;11(3):847. doi: 10.3390/jcm11030847.
引用本文的文献
1
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity.
Curr Oncol Rep. 2024 Nov;26(11):1431-1441. doi: 10.1007/s11912-024-01599-2. Epub 2024 Sep 24.
2
MEK inhibitors: a promising targeted therapy for cardiovascular disease.
Front Cardiovasc Med. 2024 Jul 1;11:1404253. doi: 10.3389/fcvm.2024.1404253. eCollection 2024.
本文引用的文献
1
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol. 2023 Jun 6;5(5):628-637. doi: 10.1016/j.jaccao.2023.04.004. eCollection 2023 Oct.
2
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review.
JACC CardioOncol. 2022 Mar 15;4(1):1-18. doi: 10.1016/j.jaccao.2022.01.096. eCollection 2022 Mar.
3
Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Curr Oncol Rep. 2022 Mar;24(3):265-271. doi: 10.1007/s11912-022-01205-3. Epub 2022 Feb 1.
4
Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
Cancer Med. 2020 Apr;9(8):2611-2620. doi: 10.1002/cam4.2922. Epub 2020 Feb 14.
Zotero 插件